Altimmune reports Q1 2024 net loss $24.4M; cash $182.1M; pemvidutide milestones on track

Altimmune, Inc.

2024-Q1 EPS reported -$0.34 revenue$5,000

Net loss $24.4M ($0.34/share) vs $20.1M ($0.40) in Q1 2023; R&D expense $21.5M on pemvidutide and HepTcell winddown.
Cash, equivalents & short-term investments $182.1M as of March 31, 2024.
Phase 2b MASH trial (IMPACT) enrollment ongoing; top-line results expected Q1 2025.
End-of-Phase 2 FDA meeting for pemvidutide obesity program expected late Q3 2024.
MOMENTUM Phase 2 data showed 74.5% weight loss from fat, 25.5% from lean mass; visceral fat preferentially reduced.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Altimmune, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, EPS $0.34 net loss per share.

Period: the first quarter ended March 31, 2024
Net income: Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share
EPS: $0.34 net loss per share
Result: reported results

Exact text from the filing

● Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, compared to a net loss of $20.1 million, or $0.40 net loss per share, in the same period in 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.